Erhan Gökmen

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations

Medicine, Oncology, Chemotherapy +10

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 565 citations

Medicine, Oncology, Breast Oncology +13

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 378 citations · Full text

Medicine, Oncology, Pharmacology +16